WHO ICTRP trial
a prospective, single-arm phase II clinical study of Envafolimab combined with…
ChiCTR2100044981 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100044981 |
|---|---|
| Public title | a prospective, single-arm phase II clinical study of Envafolimab combined with carboplatin/cisplatin and etoposide in the first-line treatment of extensive-stage SCLC |
| Scientific title | a prospective, single-arm phase II clinical study of Envafolimab combined with carboplatin/cisplatin and etoposide in the first-line treatment of extensive-stage SCLC |
| Primary sponsor | Oncology Department of PLA General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Lung Cancer |
| Interventions | Experimental group:First-line treatment with Envolimab (Envafolimab) combined with carboplatin/cisplatin and etoposide, and 4 cycles later with Envafolimab (Envafolimab) monotherapy for maintenance until the disease progresses or becomes… |
| Registration date | Apr 3, 2021 |
| Target size | Experimental group:32 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: